Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

I am receiving several questions from investors inquiring about this growth stock following its significant price decline.

Hims & Hers (NYSE: HIMS) is attracting investors looking to buy the dip in this impressive growth stock. Where to invest ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

European stocks rose sharply Friday after U.S. Commerce Secretary Howard Lutnick said the U.S. and China had agreed to restore their trade truce and that more deals were imminent. Also lifting the ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers Health Inc. investors have sued the telehealth provider days after Novo Nordisk A/S announced it was ending the ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...